Efficacy and Safety of Divozilimab in Patients With Neuromyelitis Optica Spectrum Disorders (AQUARELLE)

PHASE3Active, not recruitingINTERVENTIONAL
Enrollment

105

Participants

Timeline

Start Date

December 12, 2022

Primary Completion Date

January 31, 2025

Study Completion Date

September 30, 2026

Conditions
Neuromyelitis Optica Spectrum Disorders
Interventions
BIOLOGICAL

divozilimab

anti-CD20 monoclonal antibody

Trial Locations (19)

Unknown

"Llc Profimed", Barnaul

"Municipal Autonomous Healthcare Institution of the Order of the Red Banner of Labor City Clinical Hospital No.1", Chelyabinsk

Regional Clinical Hospital No.3, Chelyabinsk

Kuzbass Clinical Hospital named after S.V. Belyaev, Kemerovo

"Khanty-Mansiysk autonomous district - Ugra The district clinical hospital", Khanty-Mansiysk

Center for Cardiology and Neurology, Kirov

Regional Clinical Hospital № 1 named after Professor S. V. Ochapovsky, Krasnodar

Moscow Regional Clinical Research Institute named after M.F. Vladimirsky (MONIKI), Moscow

"LLC Medis", Nizhny Novgorod

Semashko Regional Clinical Hospital, Nizhny Novgorod

State Novosibirsk Regional Clinical Hospital, Novosibirsk

Pyatigorsk City Clinical Hospital No.2, Pyatigorsk

"Federal State Budgetary Educational Institution of Higher Education Rostov State Medical University", Rostov-on-Don

Pavlov First Saint Petersburg State Medical University, Saint Petersburg

Seredavin Regional Clinical Hospital, Samara

Republican Clinical Hospital No.4, Saransk

Siberian State Medical University, Tomsk

"Medical and Sanitary Unit Neftyanik", Tyumen

Ulyanovsk Regional Clinical Hospital, Ulyanovsk

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Biocad

INDUSTRY